# US 2019/0314442 A1 · Composition for the prevention or treatment of neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314442 A1
- Document ID: US20190314442A1
- Status: Published application
- Kind: A1
- Application number: 16/078,252
- Filed: 2017-02-21
- Published: 2019-10-17
- Earliest claimed: 2016-02-22
- Assignees: Newtricious B.V.
- Applicants: Newtricious B.V.
- Inventors: Paul Leopold Jonker; Sanne Maria Van Der Made; Lucas Gerardus Willibrordus Sterkman
- Web page: https://patentgrep.com/patent/US20190314442A1

## CPC

- A61K 38/018: {from milk}
- A23L 33/155: Vitamins A or D
- A23L 33/18: Peptides; Protein hydrolysates
- A61K 9/10: Dispersions; Emulsions
- A61K 35/57: Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- A61K 38/05: Dipeptides
- A61K 38/06: Tripeptides
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is in the field of the prevention, amelioration or treatment of neurodegenerative diseases, in particular of dementia including Alzheimer's disease, Huntington's Disease, Parkinson's disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The invention provides new compositions that allow an improved prevention, amelioration and treatment of such diseases. More in particular, the invention provides a composition comprising a xanthophyll and a hydrolysate of a protein, comprising di- and tripeptides.

## Claims

### Claim 1

A method for the treatment or amelioration of a neurodegenerative disease, the method comprising:
administering to subject in need thereof an aqueous composition comprising:
a. at least one xanthophyll and
b. a hydrolysate of a protein, comprising di- and tripeptides
wherein the neurodegenerative disease is selected from the group consisting of dementia, Alzheimer's disease, Huntington's Disease, Parkinson's disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis, and
wherein the protein is selected from the group consisting of lysozyme, ovomucin, ovotransferrin, ovalbumin, and casein.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the protein has been hydrosylated with an enzyme.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the enzyme is an endopeptidase.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the enzyme is selected from the group of enzymes consisting of a serine protease, subtilase, subtilisin, and Alcalase™.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition additionally comprises a pharmacologically active compound selected from the group consisting of an omega-3 fatty acid, docosahexaenoic acid, eicosapentaenoic acid, vitamin D, Uridin, Folic acid, Vitamin E, iodine, selenium, and zinc.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the di- and tri-peptides make up at least 10% of the total protein content of the composition.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the di- and tripeptides have a molecular weight of less than 0.5 kD.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the at least one xanthophyll is contained in an aqueous dispersion.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the aqueous dispersion is selected from the group consisting of skimmed milk, semi-skimmed milk, buttermilk, a buttermilk fraction, fermented milk, yoghurt, soy drink, soy milk, fermented soy milk, fruit juices, fruit purees, syrups, vegetable juices, and vegetable purees.

### Claim 10 (depends on 9)

The the method according to claim 9, wherein the aqueous dispersion is buttermilk or a buttermilk fraction.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the at least one xanthophyll is selected from the group consisting of zeaxanthin, lutein, and meso-zeaxanthin.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the composition additionally comprises egg yolk.

### Claim 13 (depends on 12)

The method according to claim 12,
wherein the at least one xanthophyll is contained in an aqueous dispersion; and
wherein the egg yolk and the aqueous dispersion are present in a weight ratio between 1:2 to 1:7.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A method according to claim 1, wherein the aqueous composition is contained in a food product.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the egg yolk and the aqueous dispersion are present in a weight ratio between 1:2 and 1:3.
